Pan-KRAS inhibitor

Pan-KRAS inhibitor for KRAS cancers

estimated prevalence



KRAS+ cancers

Genetic Source


Clinical Phase



molecule icon small molecule

BridgeBio’s pan-KRAS program targets KRASG12D and KRASG12V mutations present in a large percentage of colorectal, pancreatic and non-small cell lung cancer tumors. BridgeBio has achieved in vivo target engagement and has identified leads with promising oral bioavailability. Development candidate selection is planned for 2023.

our science

our science icon icon

our approach icon icon

patient resources icon icon